Spinning off the diagnostics division in an i.p.o. is being considered.
Company acquired license to the Georgetown assays to detect Alzheimer's.
Read the recent Yahoo news.
Zacks senior bio-tech analyst, Jason Napodano rates, it a "BUY" says it's worth three times the current share price.
Company has five assets each of which could be worth many times the company's current market cap: ESS - LymPro - MANF - MS Precise - Eltoprazine.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's Board of Directors.